New Publications
RinuaGene Biotechnology Co., Ltd. has advanced its self-developed mRNA therapeutic vaccine RG002 for HPV-related tumors and precancerous lesions into clinical development.
A research paper on this early development work, titled "Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies," has been published in the prestigious journal Molecular Therapy.
Pipeline Progress
RinuaGene Biotechnology Co., Ltd. has announced that its self-developed HPV-related therapeutic mRNA vaccine RG002 received FDA Investigational New Drug (IND) approval on October 27, 2023. This approval is for treating HPV type 16 and/or 18-related cervical intraepithelial neoplasia (CIN2/3), making it the world's first approved mRNA-LNP therapeutic vaccine for this indication.
Latest Honors
The Suzhou Science and Technology Bureau has announced the 2023 list of proposed "Unicorn Cultivation" enterprises. RinuaGene has been successfully included on this list due to its strength in technological innovation, high-quality growth, and development potential.